Tesamorelin

Tesamorelin is an FDA-approved synthetic analog of growth hormone releasing hormone (GHRH), modified at the N-terminus with a trans-3-hexenoic acid group to resist enzymatic degradation, studied for visceral fat reduction, IGF-1 normalization, and cognitive function in aging populations. The FDA approved Tesamorelin in 2010. That fact separates it from every other GHRH analog in research. Not because FDA approval implies anything about research use, but because it required a level of human clinical data that most peptides never accumulate. The trials that earned that approval generated years of published safety and efficacy data in human subjects. That is an unusual resource in this field. Tesamorelin is a stabilized analog of endogenous GHRH(1-44), modified at the N-terminus with a trans-3-hexenoic acid group that confers resistance to dipeptidyl peptidase-IV, the enzyme responsible for the rapid degradation of native GHRH in circulation. The result is a longer-acting, more bioavailable form of the same signal your hypothalamus already sends to your pituitary. Research has documented its effects across visceral adiposity reduction, IGF-1 normalization, cardiovascular lipid profiles, and most recently cognitive function in adults over 60. A randomized controlled trial found measurable improvements in executive function and verbal memory in older adults receiving Tesamorelin over 20 weeks. That is an area of research that has drawn considerable interest as the compound's profile continues to expand. For researchers who want the most clinically validated GHRH analog available, there is no equivalent.